Literature DB >> 23563670

Sphingolipids in psychiatric disorders and pain syndromes.

C Mühle1, M Reichel, E Gulbins, J Kornhuber.   

Abstract

Despite the high prevalence and devastating impact of psychiatric disorders, little is known about their etiopathology. In this review, we provide an overview on the participation of sphingolipids and enzymes responsible for their metabolism in mechanisms underlying psychiatric disorders. We focus on the pathway from sphingomyelin to proapoptotic ceramide and the subsequent metabolism of ceramide to sphingosine, which is in turn phosphorylated to yield anti-apoptotic sphingosine-1-phosphate (S1P).The sphingomyelinase/ceramide system has been linked to effects of reactive oxygen species and proinflammatory cytokines in the central nervous system as well as to synaptic transmission. Compared to ubiquitously expressed acid sphingomyelinase, acid and neutral ceramidase and neutral sphingomyelinase are highly active in brain regions. Depressed patients show elevated plasma ceramide levels and increased activities of acid sphingomyelinase which is functionally inhibited by many anti-depressive drugs. Exposure to alcohol is associated with an activation of acid and neutral sphingomyelinase observed in cell culture, mouse models and in alcohol-dependent patients and with increased concentrations of ceramide in various organs.Levels of sphingomyelin and ceramide are altered in erythrocytes and post-mortem brain tissues of schizophrenic patients in addition to changes in expression patterns for serine palmitoyltransferase and acid ceramidase leading to impaired myelination. After induction of anxiety-like behavior in animal models, higher serum levels of S1P were reported to lead to neurodegeneration. Correspondingly, S1P infusion appeared to increase anxiety-like behavior. Significantly upregulated levels of the endogenous ceramide catabolite N,N-dimethylsphingosine were observed in rat models of allodynia. Conversely, rats injected intrathecally with N,N-dimethylsphingosine developed mechanical allodynia. Moreover, S1P has been implicated in spinal nociceptive processing.The increasing interest in lipidomics and improved analytical methods led to growing insight into the connection between psychiatric and neurological disorders and sphingolipid metabolism and may once provide new targets and strategies for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23563670     DOI: 10.1007/978-3-7091-1511-4_22

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  14 in total

1.  A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.

Authors:  Carolyn D Britten; Elizabeth Garrett-Mayer; Steven H Chin; Keisuke Shirai; Besim Ogretmen; Tricia A Bentz; Alan Brisendine; Kate Anderton; Susan L Cusack; Lynn W Maines; Yan Zhuang; Charles D Smith; Melanie B Thomas
Journal:  Clin Cancer Res       Date:  2017-04-18       Impact factor: 12.531

Review 2.  Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder.

Authors:  Reza Rahimian; Claudia Belliveau; Rebecca Chen; Naguib Mechawar
Journal:  Front Psychiatry       Date:  2022-06-16       Impact factor: 5.435

3.  Modulation of sphingosine 1-phosphate (S1P) attenuates spatial learning and memory impairments in the valproic acid rat model of autism.

Authors:  Hongmei Wu; Quanzhi Zhang; Jingquan Gao; Caihong Sun; Jia Wang; Wei Xia; Yonggang Cao; Yanqiu Hao; Lijie Wu
Journal:  Psychopharmacology (Berl)       Date:  2017-12-07       Impact factor: 4.530

4.  Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's disease.

Authors:  Alfred N Fonteh; Cora Ormseth; Jiarong Chiang; Matthew Cipolla; Xianghong Arakaki; Michael G Harrington
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

5.  Behavioural traits propagate across generations via segregated iterative-somatic and gametic epigenetic mechanisms.

Authors:  Emma Mitchell; Shifra L Klein; Kimon V Argyropoulos; Ali Sharma; Robin B Chan; Judit Gal Toth; Luendreo Barboza; Charlotte Bavley; Analia Bortolozzi; Qiuying Chen; Bingfang Liu; Joanne Ingenito; Willie Mark; Jarrod Dudakov; Steven Gross; Gilbert Di Paolo; Francesc Artigas; Marcel van den Brink; Miklos Toth
Journal:  Nat Commun       Date:  2016-05-13       Impact factor: 14.919

Review 6.  From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism.

Authors:  Rolando I Castillo; Leonel E Rojo; Marcela Henriquez-Henriquez; Hernán Silva; Alejandro Maturana; María J Villar; Manuel Fuentes; Pablo A Gaspar
Journal:  Front Neurosci       Date:  2016-11-08       Impact factor: 4.677

7.  Importin α5 Regulates Anxiety through MeCP2 and Sphingosine Kinase 1.

Authors:  Nicolas Panayotis; Anton Sheinin; Shachar Y Dagan; Michael M Tsoory; Franziska Rother; Mayur Vadhvani; Anna Meshcheriakova; Sandip Koley; Letizia Marvaldi; Didi-Andreas Song; Eitan Reuveny; Britta J Eickholt; Enno Hartmann; Michael Bader; Izhak Michaelevski; Mike Fainzilber
Journal:  Cell Rep       Date:  2018-12-11       Impact factor: 9.423

8.  Monitoring the Sphingolipid de novo Synthesis by Stable-Isotope Labeling and Liquid Chromatography-Mass Spectrometry.

Authors:  Dominik Wigger; Erich Gulbins; Burkhard Kleuser; Fabian Schumacher
Journal:  Front Cell Dev Biol       Date:  2019-10-01

Review 9.  Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases.

Authors:  Sara Grassi; Laura Mauri; Simona Prioni; Livia Cabitta; Sandro Sonnino; Alessandro Prinetti; Paola Giussani
Journal:  Front Pharmacol       Date:  2019-07-23       Impact factor: 5.810

10.  System-based proteomic and metabonomic analysis of the Df(16)A+/- mouse identifies potential miR-185 targets and molecular pathway alterations.

Authors:  H Wesseling; B Xu; E J Want; E Holmes; P C Guest; M Karayiorgou; J A Gogos; S Bahn
Journal:  Mol Psychiatry       Date:  2016-03-22       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.